Search Our Scientific Publications & Authors

Publications
find publications by category +
Translate page:

Delayed Intravitreal Anti-VEGF Therapy for Patients During the COVID-19 Lockdown: An Ethical Endeavor.

Authors:
Mutasem Elfalah Saif Aldeen AlRyalat Mario Damiano Toro Robert Rejdak Sandrine Zweifel Rashed Nazzal Mohammed Abu-Ameerh Osama Ababneh Almutez Gharaibeh Zuhair Sharif Jehad Meqbil Mo'ath AlShawabkeh Amal Alwreikat Muawyah Al Bdour Maysa Al-Hussaini Yacoub A Yousef

Clin Ophthalmol 2021 17;15:661-669. Epub 2021 Feb 17.

Department of Surgery (Ophthalmology), King Hussein Cancer Center, Amman, Jordan.

Purpose: To assess the impact of Jordanian's Corona Virus Disease (COVID-19) lockdown on visual acuity and macular thickness in patients with macular edema receiving intravitreal injections, and to assess the ethical endeavor of lockdown among serious sight threatening conditions.

Patients And Methods: This retrospective observational study included patients planned for intravitreal injections who did not complete the planned course before the lockdown (ie, before 20th of March 2020). Data included demographics, indication for the intravitreal injection, corrected distance visual acuity (CDVA), and central macular thickness on Optical Coherence Tomography (OCT) before and after the lockdown.

Results: One-hundred and sixty-six eyes of 125 patients were studied, 68 (54.4%) patients were males, and the mean (± standard deviation, SD) age was 64.79 (±9.41) years. Mean (±SD) duration of delay in the planned injection was 60.97 (±24.35) days. The change in visual acuity was statistically significant for patients with diabetic macular edema (p= 0.045 improvement), patients with central retinal vein thrombosis (CRVO) (p= 0.05 deterioration), and patients with age-related macular degeneration (AMD) (p= 0.005 deterioration). Of interest, delay of more than 2 months and the previous need for 3 or more injections were significant poor prognostic factors for visual outcome for patients with diabetic macular edema (p=0.027 and 0.045).

Conclusion: The impact of delay in the scheduled intravitreal injections resulted in variable outcomes depending on the indication. Triaging the urgency of patients should be based on the indication to support the equity principle of bioethics, where those in need are prioritized against others, depending on potential adverse outcome.

Download full-text PDF

 Source
http://dx.doi.org/10.2147/OPTH.S289068DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7898208PMC
February 2021

Publication Analysis

Top Keywords

macular edema
12
visual acuity
12
intravitreal injections
12
patients
10
diabetic macular
8
patients diabetic
8
macular thickness
8
covid-19 lockdown
8
ethical endeavor
8
macular
6
injection 6097
4
6097 ±2435
4
vein thrombosis
4
±2435 days
4
planned injection
4
±sd duration
4
duration delay
4
delay planned
4
days change
4
change visual
4

Keyword Occurance

Similar Publications

Evaluation of acquired color vision deficiency in retinal vein occlusion using the Rabin cone contrast test.

Authors:
Riko Matsumoto Yoshitsugu Saishin Masahito Ohji

Graefes Arch Clin Exp Ophthalmol 2021 Apr 12. Epub 2021 Apr 12.

Department of Ophthalmology, Shiga University of Medical Science, Seta-Tsukinowacho, Otsu, Shiga, 520-2192, Japan.

Purpose: To investigate acquired color vision deficiency (CVD) using the Rabin cone contrast test (RCCT) in patients with retinal vein occlusion (RVO).

Methods: We retrospectively evaluated 39 patients with macular edema due to RVO who were treated with intravitreal injections of anti-VEGF agents and demonstrated improvement of best-corrected visual acuity to 20/20 Snellen VA or better. The acquired CVD was evaluated by the RCCT and standard pseudo-isochromatic plates-part 2 (SPP-2). Read More

View Article and Full-Text PDF
April 2021
Similar Publications

Repeatability of Optical Coherence Tomography Angiography Measurements in Patients with Retinal Vein Occlusion.

Authors:
Yong Min Lee Min Woo Lee Yong Yeon Song Seung Kook Baek Young Hoon Lee

Korean J Ophthalmol 2021 Apr 5;35(2):159-167. Epub 2021 Apr 5.

Department of Ophthalmology, Konyang University College of Medicine, Daejeon, Korea.

Purpose: To analyze the repeatability of vessel density (VD) measurements and manual foveal avascular zone (FAZ) measurements using optical coherence tomography angiography (OCTA) in patients with retinal vein occlusion (RVO) without macular edema.

Methods: The study population consisted of patients with RVO and central macular thickness <300 μm. For each subject, measurements were performed twice with a 5-minute interval. Read More

View Article and Full-Text PDF
April 2021
Similar Publications

Case of cystoid macular edema induced by systemic administration of paclitaxel: evaluations with electroretinograms.

Authors:
Kumiko Kato Ryunosuke Nagashima Masahiko Sugimoto Kengo Ikesugi Hisashi Matsubara Mineo Kondo

Doc Ophthalmol 2021 Apr 11. Epub 2021 Apr 11.

Department of Ophthalmology, Mie University Graduate School of Medicine, 2-174 Edobashi, Tsu, Mie, 514-8507, Japan.

Purpose: To report abnormal full-field electroretinograms (ERGs) in a patient with cystoid macular edema (CME) induced by systemic paclitaxel.

Methods: This is an observational case report. Full-field ERGs were recorded to evaluate the retinal function using the RETeval system and conventional ERGs using contact lens electrodes with built-in white light-emitting diodes. Read More

View Article and Full-Text PDF
April 2021
Similar Publications

Early effect of simultaneous intravitreal dexamethasone and bevacizumab combination treatment in patients with persistent diabetic macular edema.

Authors:
U Limon

J Fr Ophtalmol 2021 Apr 8. Epub 2021 Apr 8.

Health Sciences University Umraniye Training and Research Hospital Eye Clinic Istanbul, Elmalıkent Mahallesi Adem Yavuz Cad. No:1 Ümraniye, 34000 Istanbul, Turkey. Electronic address:

Purpose: To report the early effect of simultaneous intravitreal dexamethasone and bevacizumab combination treatment in patients with persistent diabetic macular edema (DME).

Methods: In this single-center prospective non-randomized study, 65 eyes of 59 patients with persistent DME were included. In the combined group (Group 1), we treated 35 eyes of 29 persistent DME patients with a simultaneous combination of intravitreal dexamethasone and bevacizumab, and in the control group (Group 2), we treated 30 eyes of 30 patients with intravitreal bevacizumab. Read More

View Article and Full-Text PDF
April 2021
Similar Publications